180,000 Shares in Haleon PLC Sponsored ADR $HLN Purchased by Milford Funds Ltd.

Milford Funds Ltd. acquired a new position in Haleon PLC Sponsored ADR (NYSE:HLN) during the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 180,000 shares of the company’s stock, valued at approximately $1,820,000.

Other large investors have also modified their holdings of the company. Stance Capital LLC acquired a new stake in shares of Haleon in the 3rd quarter worth about $34,000. Geneos Wealth Management Inc. increased its holdings in shares of Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in shares of Haleon by 428.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after acquiring an additional 5,124 shares during the period. Assetmark Inc. increased its holdings in shares of Haleon by 26.6% in the 4th quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock worth $60,000 after acquiring an additional 1,252 shares during the period. Finally, Atlantic Union Bankshares Corp increased its holdings in shares of Haleon by 69.4% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,264 shares of the company’s stock worth $63,000 after acquiring an additional 2,567 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN opened at $9.13 on Friday. The firm has a 50-day moving average price of $9.34 and a 200 day moving average price of $9.91. The firm has a market capitalization of $40.45 billion, a PE ratio of 23.42, a P/E/G ratio of 2.06 and a beta of 0.13. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 52-week low of $8.65 and a 52-week high of $11.28.

Haleon (NYSE:HLN) last announced its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The company had revenue of $3.65 billion during the quarter. On average, sell-side analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HLN has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Argus upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Haleon presently has a consensus rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.